QuantiFERON®-TB Gold Plus
blood test

Latent tuberculosis infection is a growing concern

In the US, up to 13 million people have latent tuberculosis infection (LTBI).1 Without treatment, an average 1 in 10 people with LTBI will get sick with TB disease.2 Testing for and treating LTBI in high-risk patients is the most effective way to prevent this from happening.3

Rely on the advanced TB blood test: QuantiFERON-TB Gold Plus

QuantiFERON-TB Gold Plus (QFT-Plus) is a whole-blood test or interferon-gamma release assay (IGRA) that can measure a person’s immune reactivity and aid in diagnosing Mycobacterium tuberculosis infection. It offers advantages over the conventional tuberculin skin test (TST) for diagnosing LTBI.4,5

Recommended by the Centers for Disease Control
and Prevention (CDC)

IGRA technology is the required method of TB testing for US Citizenship and Immigration Services (USCIS) immigration exams.* IGRAs are preferred by the Centers for Disease Control and Prevention (CDC) for TB testing in most risk groups, including4

  • People likely to be infected with TB
  • Anyone with low or intermediate risk of disease progression
  • People for whom it has been decided that testing for latent TB infection is warranted

IGRAs are also strongly recommended for those who are BCG-vaccinated, or unlikely to return to have their TST read.

*As of October 1, 2018.

What is the QFT-Plus advantage?

QuantiFERON-TB Gold Plus advances the science of TB blood testing, providing added benefits

  • Innovative CD4+ and CD8+ T cell responses—delivers a more comprehensive evaluation of patients’ immune response to tuberculosis infection than does QFT-TB Gold6
  • >97% specificity and >94% sensitivity6

QFT-Plus provides more flexibility:

More blood collection options, including the option to draw into 1 tube
Flexible draw times

Up to 13 million people in the US have latent TB infection1

Who should be tested?

The CDC recommends TB screening for certain at-risk patients

  • People who have spent time with someone who has TB
  • People who are immunocompromised
  • People who are high-risk substance users
  • People who live or work in high-risk congregate settings (e.g., nursing homes, colleges)
  • Healthcare workers who care for patients at increased risk for TB
  • Foreign-born persons, especially from countries with high TB incidence or prevalence
Test Name Test Code CPT Code
QuantiFERON®-TB Gold Plus—
1 Tube
36970(X) 86480
QuantiFERON®-TB Gold Plus—
4 Tube (Draw Site Incubated)
36971(X) 86480

† The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Rely on accurate, efficient, and objective TB detection

Download the QuantiFERON-TB Gold Plus flyer
Review QuantiFERON-TB Gold Plus resources
Contact a Quest sales representative

QuantiFERON-TB Gold Plus (QFT-Plus) is an in vitro diagnostic test using a peptide cocktail simulating ESAT-6 and CFP-10 proteins to stimulate cells in heparinized whole blood. Detection of interferon-γ (IFN-γ) by enzyme-linked immunosorbent assay (ELISA) is used to identify in vitro responses to these peptide antigens that are associated with Mycobacterium tuberculosis infection. QFT-Plus is an indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. This test does not differentiate between latent and active TB. Up-to-date product-specific warnings and other information can be found at www.QuantiFERON.com.


  1. Centers for Disease Control and Prevention. CDC fact sheet—TB in the United States: a snapshot. 2018.
  2. Centers for Disease Control and Prevention. Deciding when to treat latent TB infection. www.cdc.gov/tb/topic/treatment/decideltbi.htm. Accessed September 26, 2018.
  3. Centers for Disease Control and Prevention. Burden of TB in the United States. www.cdc.gov/features/burden-tb-us/index.html. Accessed September 18, 2018.
  4. Lewinsohn, DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):111-115.
  5. Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection. MMWR. 2010;59(RR05):1-25. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm.
  6. QuantiFERON-TB Gold Plus (QFT-Plus) ELISA Package Insert. 1095849 Rev. 04. July 2018.